文献速递肝病

非酒精性脂肪性肝病受试者中肌少症性肥胖的风险分层

Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-01

这项多中心回顾性研究纳入23889例接受健康筛查的非酒精性脂肪性肝病受试者(2014-2020年),肌少症性肥胖患病率为5.4%(1297/23889)。高龄、男性、肌少症指数和代谢综合征是高危肌少症性肥胖的显著危险因素;基于高危筛查模型,高危肌少症性肥胖受试者发生显著肝纤维化或心血管疾病的比值显著高于无肌少症性肥胖者。

要点

  • 非酒精性脂肪性肝病受试者中肌少症性肥胖患病率为5.4%(1297/23889)。
  • 高龄、男性、肌少症指数和代谢综合征是高危肌少症性肥胖的显著危险因素。
  • 高危肌少症性肥胖受试者发生显著肝纤维化或心血管疾病的比值显著高于无肌少症性肥胖者。

核心结论

  • 高危筛查模型可能有助于识别非酒精性脂肪性肝病中高危肌少症性肥胖受试者。

研究设计与样本

  • 多中心回顾性研究纳入23889例接受健康筛查项目的非酒精性脂肪性肝病受试者(2014-2020年)。
  • 肌少症依据性别特异性肌少症指数截断值并使用多频生物电阻抗分析定义。

主要发现

  • 肌少症性肥胖患病率为5.4%(1297/23889)。
  • 高龄(非标准化β=3.23;P<.001)、男性(β=1.66;P=.027)、肌少症指数(β=-6.25;P=.019)和代谢综合征(β=1.75;P<.001)是高危肌少症性肥胖的显著危险因素。
  • 基于高危肌少症性肥胖筛查模型,高危肌少症性肥胖受试者发生显著肝纤维化的比值显著高于无肌少症性肥胖者(训练集:aOR=3.72;验证集:aOR=2.38)。
  • 高危肌少症性肥胖受试者发生心血管疾病的比值显著高于无肌少症性肥胖者(训练集:aOR=5.20;验证集:aOR=3.71)(所有P<.001)。
  • 在纵向队列中,考虑全因死亡和肝移植为竞争风险,高危肌少症性肥胖受试者显著肝纤维化或心血管疾病的累积发生率显著高于低危肌少症性肥胖受试者(亚分布风险比=5.37;P<.001)。

关键数值与推荐

  • 高危肌少症性肥胖定义为纤维化-4指数>2.67提示显著肝纤维化或动脉粥样硬化性心血管疾病风险评分>20%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The impact of the severity of sarcopenic obesity (SO) in nonalcoholic fatty liver disease (NAFLD) on the risk of significant liver fibrosis or cardiovascular disease (CVD) remains unclear. We aimed to identify high-risk subjects with SO for significant liver fibrosis or CVD among subjects with SO and NAFLD. METHODS: This multicenter, retrospective study involved 23,889 subjects with NAFLD who underwent a health screening program (2014-2020). Sarcopenia was defined based on gender-specific sarcopenia index cutoff using multi-frequency bioelectric impedance analysis. High-risk subjects with SO were defined as those with significant liver fibrosis by fibrosis-4 index >2.67 or atherosclerotic CVD risk score >20%. Multivariable logistic regression analysis for identifying high-risk subjects with SO was performed in a cross-sectional cohort with SO, and further validation was performed in a longitudinal cohort. RESULTS: SO prevalence was 5.4% (n = 1297 of 23,889). Older age (unstandardized beta [β] = 3.23; P < .001), male (β = 1.66; P = .027), sarcopenia index (β = -6.25; P = .019), and metabolic syndrome (β = 1.75; P < .001) were significant risk factors for high-risk SO. Based on a high-risk SO screening model, high-risk subjects with SO had significantly higher odds of significant liver fibrosis (training: adjusted odds ratio [aOR], 3.72; validation: aOR, 2.38) or CVD (training: aOR, 5.20; validation: aOR, 3.71) than subjects without SO (all P < .001). In subgroup analyses, the cumulative incidence of significant liver fibrosis or CVD development was significantly higher in high-risk subjects with SO than in low-risk subjects with SO in a longitudinal cohort considering all-cause mortality and liver transplantation as competing risks (sub-distribution hazard ratio, 5.37; P < .001). CONCLUSION: The high-risk screening model may enable the identification of high-risk subjects with SO with NAFLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chun HS, Lee M, Lee HA, et al. Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022. PMID: 36462755. doi:10.1016/j.cgh.2022.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。